The aim of this study was to report hand function, disability and satisfaction and patients’ perception of functionally troublesome contractures 5 years after injection with collagenase Clostridium histolyticum and hand therapy for Dupuytren's disease. Data from 79 patients were collected before and at 3, 12 and 60 months after treatment. Hand function was significantly improved, and 70% achieved a functional range of motion in the treated hand. QuickDASH scores and range of motion were best at 3 months follow-up. At 60 months, mean total extension deficit was 48°, which was 57% of the deficit before treatment. Thirty-seven patients (47%) had developed recurrent contractures in treated finger(s) meeting the criteria for new treatment. The threshold for functionally troublesome contractures was found to be 30°–60° in the finger joints. Treatment was experienced as painful, but few hand function problems occurred. Most patients would choose this treatment method again.
AltmanDGBlandJM. Statistics notes. Units of analysis. BMJ. 1997, 314: 1874.
2.
AtroshiIGummessonCAnderssonBDahlgrenEJohanssonA. The Disabilities of the Arm, Shoulder and Hand (DASH) outcome questionnaire: reliability and validity of the Swedish version evaluated in 176 patients. Acta Orthop Scand. 2000, 71: 613–8.
3.
BainGIPolitesNHiggsBGHepinstallRJMcGrathAM. The functional range of motion of the finger joints. J Hand Surg Eur. 2015, 40: 406–11.
4.
BallCPrattALNanchahalJ. Optimal functional outcome measures for assessing treatment for Dupuytrens disease: a systematic review and recommendations for future practice. BMC Muskuloskelet Disord. 2013, 14: 131.
5.
Bell Krotoski J. Sensibility testing. In: Skirven T, Osterman L, Fedorczyk J, Amadio P (Eds.) Rehabilitation of the hand and upper extremity, 6th edn. Philadelphia: Elsevier/Mosby, 2011, 1: 132–51.
6.
BradleyJWarwickD. Patient satisfaction with collagenase. J Hand Surg Am. 2016, 41: 689–97.
7.
BryantDHaveyTCRobertsRGuyattG. How many patients? How many limbs? Analysis of patients or limbs in the orthopedic literature, a systematic review. J Bone Joint Surg Am. 2006, 88: 41–5.
8.
FranchignoniFVercelliSGiordanoASartorioFBraviniEFerrieroG. Minimal clinically important difference of the Disabilities of the Arm, Shoulder and Hand outcome measure (DASH) and its shortened version (QuickDASH). J Orthop Sports Phys Ther. 2014, 44: 30–9.
9.
GastonRGLarsenSEPessGM; et al.The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 2015, 40: 1963–71.
HurstLBadalamenteMHentzV; et al.Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009, 361: 968–79.
13.
KanHJde Bekker-GrobEWvan MarionES; et al.Patients' preferences for treatment for Dupuytren's disease: a discrete choice experiment. Plast Reconstr Surg. 2016, 137: 165–73.
14.
KanHJVerrijpFWHoviusSEvan NieuwenhovenCADupuytren Delphi GroupSellesRW. Recurrence of Dupuytren's contracture: a consensus-based definition. PLoS ONE. 2017, 12: e0164849.
15.
KaplanFTDCrosbyN. Treatment of recurrent Dupuytren disease. Hand Clin. 2018, 34: 403–15.
16.
KingICBelcherHJ. Cold intolerance following collagenase clostridium histolyticum treatment for Dupuytren Contracture. J Hand Surg Am. 2014, 39: 808–9.
17.
Layton T, Nanchahal J. Recent advances in the understanding of Dupuytren’s disease. F1000Res. 2019, 8, F1000 Faculty rev 231. https://doi.org/10.12688/f1000research.17779.1 (accessed 20 October 2020).
18.
LeclèreFMKohlSVaronierCUnglaubFVögelinE. Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana Stage 1–3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients. Arch Orthop Trauma Surg. 2018, 138: 1623–31.
19.
MatthewsJNAltmanDGCampbellMJRoystonP. Analysis of serial measurements in medical research. BMJ. 1990, 300: 230–5.
20.
MckirdySJacobsNNassabRStarleyI. Retrospective review of cold intolerance following corrective surgery for Dupuytren's disease. Br J Hand Ther. 2007, 12: 55–9.
21.
MickelsonDTNolandSSWattAJKollitzKMVedderNBHuangJI. Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg Am. 2014, 39: 1933–41.
22.
NamaziHMajdZ. Cold intolerance following collagenase clostridium histolyticum treatment for Dupuytren contracture: a molecular mechanism. J Hand Surg Am. 2014, 39: 1886–7.
23.
NordenskjöldJLauritzsonAÅkessonAAtroshiI. Collagenase injections for Dupuytren disease: 3-year treatment outcomes and predictors of recurrence in 89 hands. Acta Orthop. 2019, 90: 517–22.
24.
NordenskjöldJWaldénMKjellinAFranzénHAtroshiI. Benefit of local anesthesia in reducing pain during collagenase injection for Dupuytren’s contracture. Plast Reconstr Surg. 2017, 140: 565–9.
25.
PeimerCABlazarPColemanSKaplanFTSmithTLindauT (2015a) Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [collagenase option for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg Am40: 1597–605.
26.
PeimerCAWilbrandSGerberRAChapmanDSzczypaPP (2015b) Safety and tolerability of collagenase clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur40: 141–9.
27.
PrattALBallC. What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practice. BMC Musculoskelet Disord. 2016, 17: 20.
28.
RaymondAParryMAmirfeyzR. Critical angles of deformity in Dupuytren’s contracture of the little and ring fingers. Hand Surg. 2015, 20: 290–7.
29.
RodriguesJNZhangWScammellBEDavisTRC. Dynamism in Dupuytren’s contractures. J Hand Surg Eur. 2015, 40: 166–70.
30.
RodriguesJNZhangWScammellBE; et al.Validity of the Disabilities of the Arm, Shoulder and Hand patient reported outcome measure (DASH) and the QuickDASH when used in Dupuytren’s disease. J Hand Surg Eur. 2016, 41: 589–99.
31.
Sanjuan-CerveroRCarrera-HuesoFVazquez-FerreiroPGomez-HerreroD. Adverse effects of collagenase in the treatment of Dupuytren disease: a systematic review. BioDrugs. 2017, 31: 105–15.
32.
StrömbergJSörensenAIFridénJ. Percutaneus needle fasciotomy versus collagenase treatment for Dupuytren contracture. A randomized controlled trial with a two-year follow-up. J Bone Joint Surg Am. 2018, 100: 1079–86.
33.
TangJBGiddinsG. Why and how to report surgeons’ levels of expertise. J Hand Surg Eur. 2016, 41: 365–6.
34.
Van RijssenALter LindenHWerkerPM. Five-year results of a randomized clinical trial on treatment in Dupuytren’s disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012, 129: 469–77.
35.
WerlinrudJHansenKLarsenSLauritsenJ. Five-year results after collagenase treatment of Dupuytren disease. J Hand Surg Eur. 2018, 43: 841–7.
36.
ZhaoJHadleySFloydEEarpBBlazarP. The impact of collagenase clostridium histolyticum. Introduction on Dupuytren treatment patterns in the United States. J Hand Surg Am. 2016, 41: 963–8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
